Managerial Innovation in Hospitals: An Analysis of Adoption of Micro Costing
Author(s)
Silvana Secinaro , Paolo Pietro Biancone , Valerio Brescia , Giovanni Paride Verardi , Maha Radwan , Cristina Gentili , Giulia Stola , Cinzia Auriti , Bianca Maria Goffredo , Valeria Antenucci ,
Download Full PDF Pages: 87-93 | Views: 1037 | Downloads: 320 | DOI: 10.5281/zenodo.3496911
Abstract
The accounting information associated with clinical results is able to map the real cost efficiency in the clinical trial. The study analyzes explicitly the clinical trial carried out in 2017 by the "Bambin Gesù" Pediatric Hospital in Rome (Italy). The survey for the first time classifies the costs of a clinical trial on the use of micafungin in pediatric patients. The study provides an example of ways and items of expenses related to the clinical trial. The methodology used is applicable and can be used to compare future trials, thus identifying reference benchmarks. The study through practical application seeks to identify the correct method to avoid errors during the detection of clinical trials as evidenced by the study by Graves et al. (2002) through a proper application. The article also highlights the main cost items to be kept under control during the clinical trial phases. Moreover, given the incidence of candida in children, the study increases the literature on the administration and testing of specific drugs for treatment and therapy
Keywords
clinical trial; micro-costing approach; micafungin; pediatric
References
i. Arrieta, A. C., Maddison, P., & Groll, A. H. (2011). Safety of micafungin in pediatric clinical trials. The Pediatric infectious disease journal, 30(6), e97–e102.
ii. Auriti, C., Falcone, M., Ronchetti, M. P., Goffredo, B. M., Cairoli, S., Crisafulli, R., … Pai, M. P. (2016). High-dose micafungin for preterm neonates and infants with invasive and central nervous system candidiasis. Antimicrobial agents and chemotherapy, 60(12), 7333–7339.
iii. Auriti, C., Piersigilli, F., Ronchetti, M. P., Campi, F., Amante, P. G., Falcone, M., & Goffredo, B. M. (2016). Shunt lock therapy with micafungin to treat shunt-associated Candida albicans meningitis in an infant. Journal of Antimicrobial Chemotherapy, 71(7), 2060–2061.
iv. Benjamin, D. K., DeLong, E., Cotten, C. M., Garges, H. P., Steinbach, W. J., & Clark, R. H. (2004). Mortality following blood culture in premature infants: Increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. Journal of Perinatology, 24(3), 175.
v. Benjamin, D. K., Stoll, B. J., Fanaroff, A. A., McDonald, S. A., Oh, W., Higgins, R. D., … Goldberg, R. (2006). Neonatal candidiasis among extremely low birth weight infants: Risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics, 117(1), 84–92.
vi. Benjamin Jr, D. K., Deville, J. G., Azie, N., Kovanda, L., Roy, M., Wu, C., & Arrieta, A. (2013). Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis. The Pediatric infectious disease journal, 32(11).
vii. Biancone, P. P., Tradori, V., De Bernardi, P., & Brescia, V. (2018). L’approccio del micro-costing nell’analisi comparativa della gestione delle ulcere peptiche in fase acuta. Alcune evidenze empiriche. MECOSAN. Menagement e economia sanitaria, 2018(106), 93–110.
viii. Biancone, P., Secinaro, S., Brescia, V., & Calandra, D. (2019). The Medical Record and the Cycle of Innovation in the Clinical Pathway of Patients Suffering from Pathological Addictions. In 14 th International Forum on Knowledge Asset Dynamics (pp. 1610-1623). IFKAD 2019, Institute of Knoledge Asset Management, Arts for Business Intitute, University of Basilicata.
ix. Bochennek, K., Balan, A., Müller-Scholden, L., Becker, M., Farowski, F., Müller, C., … Lehrnbecher, T. (2015). Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease. Journal of Antimicrobial Chemotherapy, 70(5), 1527–1530.
x. Denzin, N. K., & Lincoln, Y. S. (2002). The qualitative inquiry reader. Sage.
xi. Eisenhardt, K. M. (1989). Building theories from case study research. Academy of management review, 14(4), 532–550.
xii. Frick, K. D. (2009). Micro-costing quantity data collection methods. Medical care, 47(7 Suppl 1), S76.
xiii. Glaser, B. G., & Strauss, A. L. (1967). The discovery ofgrounded theory: Strategiesfor qualitative research. Chicago: Aldire.
xiv. Graves, N., Walker, D., Raine, R., Hutchings, A., & Roberts, J. A. (2002). Cost data for individual patients included in clinical studies: No amount of statistical analysis can compensate for inadequate costing methods. Health Economics, 11(8), 735–739.
xv. Hope, W. W., Smith, P. B., Arrieta, A., Buell, D. N., Roy, M., Kaibara, A., … Benjamin, D. K. (2010). Population pharmacokinetics of micafungin in neonates and young infants. Antimicrobial agents and chemotherapy, 54(6), 2633–2637.
xvi. Kawaguchi, C., Arai, I., Yasuhara, H., Sano, R., Nishikubo, T., & Takahashi, Y. (2009). Efficacy of micafungin in treating four premature infants with candidiasis. Pediatrics International, 51(2), 220–224.
xvii. Kobayashi, C., Hanadate, T., Niwa, T., Yoshiyasu, T., So, M., & Matsui, K. (2015). Safety and effectiveness of micafungin in Japanese pediatric patients: Results of a postmarketing surveillance study. Journal of pediatric hematology/oncology, 37(5), e285.
xviii. Kovanda, L. L., Walsh, T. J., Benjamin Jr, D. K., Arrieta, A., Kaufman, D. A., Smith, P. B., … Bonate, P. L. (2018). Exposure–response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials. The Pediatric infectious disease journal, 37(6), 580.
xix. Leroux, S., Jacqz-Aigrain, E., Elie, V., Legrand, F., Barin-Le Guellec, C., Aurich, B., … Coopman, S. (2018). Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: A randomized, open-label clinical trial. British journal of clinical pharmacology, 84(9), 1989–1999.
xx. Makhoul, I. R., Sujov, P., Smolkin, T., Lusky, A., & Reichman, B. (2002). Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: A national survey. Pediatrics, 109(1), 34–39.
xxi. Maximova, N., Schillani, G., Simeone, R., Maestro, A., & Zanon, D. (2017). Comparison of efficacy and safety of caspofungin versus micafungin in pediatric allogeneic stem cell transplant recipients: A retrospective analysis. Advances in therapy, 34(5), 1184–1199.
xxii. Minami, T., Serlin, R. C., Wampold, B. E., Kircher, J. C., & Brown, G. J. (2008). Using clinical trials to benchmark effects produced in clinical practice. Quality and Quantity, 42(4), 513.
xxiii. Nguyen, Q., MHIMe, D. M., & Ellis, D. (2009). Not just little adults: Candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. peds, 2008, 2055.
xxiv. Queiroz-Telles, F., Berezin, E., Leverger, G., Freire, A., van der Vyver, A., Chotpitayasunondh, T., ... & Arrieta, A. (2008). Micafungin Invasive Candidiasis Study Group: Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J, 27(9), 820-826.
xxv. Santolaya, M. E., Matute, T. A., de Queiroz Telles, F., Colombo, A. L., Zurita, J., Tiraboschi, I. N., ... & Echevarría, J. (2013). Recommendations for the management of candidemia in neonates in Latin America. Revista iberoamericana de micologia, 30(3), 158-170.
xxvi. Schonfeld, W., Cheng, J. W., Tong, K. B., & Seifeldin, R. (2008). Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clinical therapeutics, 30(5), 964-973.
xxvii. Schreyögg, J. (2008). A micro‐costing approach to estimating hospital costs for appendectomy in a Cross‐European context. Health Economics, 17(S1), S59-S69.
xxviii. Tradori, V., De Bernardi, P., & Brescia, V. (2019). The Micro-Costing Approach to Foster the Effectiveness of Decision-Making Processes in the Healthcare System–Some Empirical Evidence from the Piedmont Region. INTERNATIONAL JOURNAL OF BUSINESS AND MANAGEMENT, 14(2), 167–179.
Cite this Article: